- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01165216
Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer
23 juni 2014 uppdaterad av: Bristol-Myers Squibb
Phase 1 Study of Ipilimumab (BMS-734016) in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer
The primary purpose of this study was to establish the recommended dose of ipilimumab administered in combination with paclitaxel and carboplatin in Japanese patients with nonsmall-cell lung cancer.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
15
Fas
- Fas 1
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Tokyo
-
Chuo-ku, Tokyo, Japan, 1040045
- Local Institution
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Key Inclusion Criteria:
- Histologically or cytologically documented nonsmall-cell lung cancer (NSCLC) presenting as stage IIIB disease without indications for definitive radiotherapy, stage IV disease, or recurrent disease following radiation therapy or surgical resection
- No prior chemotherapy, hormonal therapy, immunotherapy, or targeted-therapy-containing regimens for the treatment of NSCLC
- Life expectancy of at least 3 months
- Eastern Cooperative Oncology Group performance score of 0-1
- Adequate bone marrow function
- Hemoglobin ≥9.0 g/dL
- Absolute neutrophil count ≥1,500/mm^3
- Platelet count ≥100,000/mm^3
- Adequate liver function
- Total bilirubin level ≤2.0*the upper limit of normal (ULN)
- Asparate aminotransferase level ≤2.5*ULN
- Alanine aminotransferase level ≤2.5*ULN
- Adequate renal function
- Calculated creatinine clearance based on Cockcroft and Gault formula ≥50 mL/min.
Key Exclusion Criteria:
- Symptomatic central nervous system (CNS) metastasis or active CNS metastasis requiring medication
- Malignant body cavity fluid (eg, pleural effusion, cardiac effusion, ascites) that recurred despite appropriate supportive care
- Prior radiation of ≥30% of major bone-marrow containing areas (pelvis, lumbar spine)
- Documented history of severe autoimmune or immune-mediated symptomatic disease that required prolonged (longer than 2 months) systemic immunosuppressant treatment
- Documented history of motor neuropathy considered of autoimmune origin (eg, Guillain Barré syndrome)
- Any concurrent malignancy other than nonmelanoma skin cancer, carcinoma in situ of the cervix, carcinoma in situ of the breast, carcinoma of the mucous membrane of the gastrointestinal tract, or superficial bladder cancer treated with systemic therapy
- ≥Grade 2 diarrhea
- History of or concurrent disease of gastrointestinal tract perforations
- ≥Grade 2 peripheral neuropathy (motor or sensory)
- Uncontrolled intercurrent illness including infection requiring systemic therapy, symptomatic congestive heart failure, uncontrolled hypertension, uncontrolled angina pectoris, uncontrolled peptic ulcer, and cardiac arrhythmia requiring medication
- Positive finding for human immunodeficiency virus antibody, hepatitis B surface antigen, or hepatitis C virus antibody.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Dose Level 1: Ipilimumab, 3 mg/kg + Paclitaxel + Carboplatin
Participants received ipilimumab, 3 mg/kg, administered as a single dose intravenously (IV) over 90 minutes every 3 weeks, plus paclitaxel, 175 mg/m^2 , administered as a single dose IV over 3 hours every 3 weeks (up to 6 doses), and carboplatin, area under the curve (AUC)=6, administered as a single dose IV over 30-60 minutes every 3 weeks (up to 6 doses).
|
Intervenous (IV) injection, administered every 3 weeks for up to 6 cycles
IV injection, 175 mg/m^2, administered every 3 weeks for up to 6 cycles
IV injection, AUC=6, administered every 3 weeks for up to 6 cycles.
(AUC=area under the concentration curve)
|
Experimentell: Dose Level 2: Ipilimumab, 10 mg/kg + Paclitaxel + Carboplatin
Participants received ipilimumab, 10 mg/kg, administered as a single dose IV over 90 minutes every 3 weeks, plus paclitaxel, 175 mg/m^2 , administered as a single dose IV over 3 hours every 3 weeks (up to 6 doses), and carboplatin, AUC=6, administered as a single dose IV over 30-60 minutes every 3 weeks (up to 6 doses).
|
IV injection, 175 mg/m^2, administered every 3 weeks for up to 6 cycles
IV injection, AUC=6, administered every 3 weeks for up to 6 cycles.
(AUC=area under the concentration curve)
IV injection, administered every 3 weeks for up to 6 cycles
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of Participants Experiencing a Dose-limiting Toxicity (DLT)
Tidsram: Day 1 of Cycles 1 and 2 From Day 1 of Cycle 3 to Day 21 of Cycle 4
|
A DLT was defined as study drug-related adverse event occurring during the first 2 cycles after ipilimumab administration in the induction phase and was any of the following: Grade 4 absolute neutrophil count (ANC) decreased (<500 cells/ mm^3) for 7 or more consecutive days; febrile Neutropenia (body temperature ≥38.5°
C with ANC <1000 /mm^3) lasting >3 days; Grade 4 platelet count decreased (<25,000 cells/mm^3) or Grade 3 platelet count decreased requiring a platelet transfusion; Grade 3 or greater nausea, vomiting, diarrhea, despite the use of adequate/maximal medical intervention; Grade 3 or greater aspartate transaminase/alanine transaminase level and rash that has not resolved to Grade 2 or lower within 2 weeks after onset; or any Grade 3 or greater nonhematologic toxicity (except Grade 3 fatigue, Grade 3 asthenia, Grade 3 transient arthralgia/myalgia, or Grade 3 transient abnormal electrolyte levels).
|
Day 1 of Cycles 1 and 2 From Day 1 of Cycle 3 to Day 21 of Cycle 4
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Drug-related Adverse Events (AEs), AEs Leading to Discontinuation, Drug-related AEs Leading to Discontinuation
Tidsram: Continuously from Day 1 to Week 24 and every12 weeks thereafter during maintenance until discontinuation of drug
|
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.
SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Treatment-related=having certain, probable, possible, or unknown relationship to study drug.
AE incidence was assessed from Day 1 until Week 24 and every 12 weeks thereafter during the maintenance period, until discontinuation of study drug, due to progression of disease, toxicities requiring discontinuation, withdrawal of consent, or study closure, and at least every 4 weeks(±1 week) until all study drug-related toxicities had recovered to resolved, stabilized or returned to baseline or were deemed irreversible during the follow-up period).
|
Continuously from Day 1 to Week 24 and every12 weeks thereafter during maintenance until discontinuation of drug
|
Number of Participants With Best Overall Response (BOR) of Partial Response (PR) or Stable Disease
Tidsram: Day 1 of Cycle 3, Day 1 of Cycle 5, and Day 22 of Cycle 6
|
Tumor response was determined for all participants with measurable lesions by radiologic responses as defined by Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.
The BOR was the best response recorded from start of treatment until disease progression/recurrence.
RECIST for target lesions: PR=at least a 30% decrease in the sum of the longest dimension (LD) of target lesions, taking as reference the baseline sum LD; stable disease=neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum LD since the treatment started.
At minimum, tumor measurements were to be obtained at screening, every 6 weeks (±1 week) during the induction phase and every 12 weeks (±1 week) during the maintenance phase.
|
Day 1 of Cycle 3, Day 1 of Cycle 5, and Day 22 of Cycle 6
|
Maximum Serum Concentration (Cmax) of Ipilimumab
Tidsram: During Cycle 3: predose and 1.5, 4, 24, 48, 168, and 336 hours postdose ipilimumab
|
Cmax was recorded directly from experimental observations.
Actual times were used for the analyses.
Cmax measurements were performed during the 3rd cycle; at predose and at 1.5, 4 , 24 (Day 2), 48 (Day 3), 168 hrs (Day 8),and 336 (Day 15) hours postdose; during the 4th and subsequent cycle, predose ipilimumab; and off-treatment until progression of disease, toxicities requiring discontinuation, withdrawal of consent, or study closure.
|
During Cycle 3: predose and 1.5, 4, 24, 48, 168, and 336 hours postdose ipilimumab
|
Trough Observed Serum Concentration (Cmin) of Ipilimumab
Tidsram: During Cycle 3: predose and 1.5, 4, 24, 48, 168, and 336 hours postdose ipilimumab
|
Cmin was recorded directly from experimental observations.
Actual times were used for the analyses.
Cmin measurements were performed during the 3rd cycle, at predose and at 1.5, 4 , 24 (Day 2), 48 (Day 3), 168 (Day 8), and 336 (Day 15) hours postdose; during the 4th and subsequent cycle, predose ipilimumab; and off-treatment until progression of disease, toxicities requiring discontinuation, withdrawal of consent; or study closure.
|
During Cycle 3: predose and 1.5, 4, 24, 48, 168, and 336 hours postdose ipilimumab
|
Area Under the Concentration Curve From Time 0 to Day 21 (in 1 Interval Dosing) (AUC[0-21d]) for Ipilimumab
Tidsram: During Cycle 3: predose and 1.5, 4, 24, 48, 168, and 336 hours postdose ipilimumab
|
The AUC(0-21d) was calculated using a mixture of log- and linear-trapezoidal summations.
Using no weighting factor, the terminal log-liner phase of the concentration-time curve was determined by least-square linear regression of at least 3 data points.
Individual patient pharmacokinetic (PK) parameter values were derived by noncompartmental methods using a validated PK analysis program.
Actual times were used for the analyses.
AUC(0-21d) measurements were performed during the 3rd cycle, at predose and at 1.5, 4 , 24 (Day 2), 48 (Day 3), 168 hrs (Day 8),and 336 (Day 15) hours postdose; during the 4th and subsequent cycle, predose ipilimumab; and off-treatment until progression of disease, toxicities requiring discontinuation, withdrawal of consent; or study closure.
|
During Cycle 3: predose and 1.5, 4, 24, 48, 168, and 336 hours postdose ipilimumab
|
Time of Maximum Observed Serum Concentration (Tmax)
Tidsram: During Cycle 3: predose and 1.5, 4, 24, 48, 168, and 336 hours postdose ipilimumab
|
Tmax was recorded directly from experimental observations.
Actual times were used for the analyses.
Tmax measurements were performed during the 3rd cycle; at predose and at 1.5, 4 , 24 (Day 2), 48 (Day 3), 168 hrs (Day 8),and 336 (Day 15) hours postdose; during the 4th and subsequent cycle, predose ipilimumab; and off-treatment until progression of disease, toxicities requiring discontinuation, withdrawal of consent, or study closure.
|
During Cycle 3: predose and 1.5, 4, 24, 48, 168, and 336 hours postdose ipilimumab
|
Serum Half-life (T-HALF) of Ipilimumab
Tidsram: During Cycle 3: predose and 1.5, 4, 24, 48, 168, and 336 hours postdose ipilimumab
|
T-HALF was calculated as the ratio of ln(2) to elimination rate constant (K), where K was estimated as negative slope obtained by regression of the terminal log-linear portion of the serum concentration vs time profile following the ipilimumab dose on Day 1 of Cycle 3. Individual patient pharmacokinetic (PK) parameter values were derived by noncompartmental methods, using a validated PK analysis program.
Actual times were used for the analyses.
T-HALF measurements were performed during the 3rd cycle; at predose and at 1.5, 4 , 24 (Day 2), 48 (Day 3), 168 hrs (Day 8),and 336 (Day 15) hours postdose; during the 4th and subsequent cycle, predose ipilimumab; and off-treatment until progression of disease, toxicities requiring discontinuation, withdrawal of consent, or study closure.
|
During Cycle 3: predose and 1.5, 4, 24, 48, 168, and 336 hours postdose ipilimumab
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Användbara länkar
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 september 2010
Primärt slutförande (Faktisk)
1 juni 2013
Avslutad studie (Faktisk)
1 juni 2013
Studieregistreringsdatum
Först inskickad
16 juli 2010
Först inskickad som uppfyllde QC-kriterierna
16 juli 2010
Första postat (Uppskatta)
19 juli 2010
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
22 juli 2014
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
23 juni 2014
Senast verifierad
1 juni 2014
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Luftvägssjukdomar
- Neoplasmer
- Lungsjukdomar
- Neoplasmer efter plats
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Karcinom, bronkogent
- Bronkiella neoplasmer
- Lungneoplasmer
- Karcinom, icke-småcellig lunga
- Molekylära mekanismer för farmakologisk verkan
- Antineoplastiska medel
- Tubulin modulatorer
- Antimitotiska medel
- Mitosmodulatorer
- Antineoplastiska medel, fytogena
- Antineoplastiska medel, immunologiska
- Immune Checkpoint-hämmare
- Karboplatin
- Paklitaxel
- Ipilimumab
Andra studie-ID-nummer
- CA184-113
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Icke-småcellig lungcancer
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeRefraktärt mogen T-cell och NK-cell non-Hodgkin lymfom | Mogen T-cell och NK-cell non-Hodgkin lymfom | Återkommande moget T- och NK-cells non-Hodgkin-lymfom | Återkommande kutant T-cell non-Hodgkin lymfom | Refraktärt kutant T-cell non-Hodgkin lymfomFörenta staterna
-
National Cancer Institute (NCI)AvslutadÅterkommande kutant T-cell non-Hodgkin lymfom | Steg I Kutant T-cell non-Hodgkin lymfom | Steg II Kutant T-cell non-Hodgkin lymfomFörenta staterna
-
Stanford UniversityNational Institutes of Health (NIH); AmgenAvslutadLymfom, icke-Hodgkin | Lymfom: Non-Hodgkin | Lymfom: Icke-Hodgkin perifer T-cell | Lymfom: Non-Hodgkin kutant lymfom | Lymfom: Non-Hodgkin Diffus Stor B-cell | Lymfom: Non-Hodgkin follikulära / indolenta B-cell | Lymfom: Non-Hodgkin Mantle Cell | Lymfom: Non-Hodgkin Marginal Zone | Lymfom: Non-Hodgkin...Förenta staterna
-
Novartis PharmaceuticalsAvslutadMelanom | Trippel negativ bröstcancer | Anaplastisk sköldkörtelcancer | Andra fasta tumörer | Non-small Sell Lung Cancer (NSCLC)Förenta staterna, Italien, Spanien, Ungern, Taiwan, Tyskland, Nederländerna, Frankrike, Norge, Polen, Thailand, Libanon, Kalkon, Kanada
-
John ReneauAktiv, inte rekryterandeÅterkommande T-cell non-Hodgkin lymfom | Återkommande primärt kutant T-cells non-Hodgkin-lymfom | Steg III kutant T-cell non-Hodgkin lymfom | Steg IV Kutant T-cell non-Hodgkin lymfom | Primärt kutant anaplastiskt storcelligt lymfom | Refraktärt primärt kutant T-cells non-Hodgkin-lymfom | Lymfomatoid... och andra villkorFörenta staterna
-
City of Hope Medical CenterNational Cancer Institute (NCI)AvslutadAnaplastiskt storcelligt lymfom | Återkommande mogna T-cell och NK-cell non-Hodgkin lymfom | Refraktärt mogen T-cell och NK-cell non-Hodgkin lymfomFörenta staterna
-
Walter HanelAktiv, inte rekryterandeÅterkommande mogna T-cell och NK-cell non-Hodgkin lymfom | Återkommande primärt kutant T-cells non-Hodgkin-lymfom | Refraktärt mogen T-cell och NK-cell non-Hodgkin lymfom | Refraktärt anaplastiskt storcelligt lymfom | T-cell non-Hodgkin lymfom | Refraktärt primärt kutant T-cells non-Hodgkin-lymfom och andra villkorFörenta staterna
-
National Cancer Institute (NCI)RekryteringRefraktärt B-cells non-Hodgkin-lymfom | Refraktärt T-cell non-Hodgkin lymfom | Återkommande B-cells non-Hodgkin lymfom | Återkommande transformerat non-Hodgkin-lymfom | Återkommande non-Hodgkin lymfom | Refraktärt non-Hodgkin lymfom | Återkommande T-cell non-Hodgkin lymfom | Återkommande primärt kutant... och andra villkorFörenta staterna
-
Mayo ClinicRekryteringIndolent B-cell non-Hodgkin lymfom | Återkommande indolent non-Hodgkin-lymfom | Refraktärt indolent non-Hodgkin-lymfom | Återkommande indolent B-cell non-Hodgkin lymfom | Refraktärt indolent B-cell non-Hodgkin lymfomFörenta staterna
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)AvslutadÅterkommande Hodgkin-lymfom | Refraktärt Hodgkin-lymfom | Refraktärt B-cells non-Hodgkin-lymfom | Refraktärt T-cell non-Hodgkin lymfom | Återkommande B-cells non-Hodgkin lymfom | Återkommande T-cell non-Hodgkin lymfomFörenta staterna
Kliniska prövningar på Ipilimumab, 3 mg
-
Bristol-Myers SquibbAvslutadMelanomFrankrike, Kanada, Förenta staterna, Tyskland, Australien, Ryska Federationen, Spanien, Italien, Nederländerna, Polen, Danmark, Israel, Storbritannien
-
Baptist Health South FloridaBristol-Myers Squibb; NovoCure Ltd.AvslutadÅterkommande glioblastomFörenta staterna
-
University Health Network, TorontoAvslutadTidigare obehandlad och histologiskt bekräftad Steg III (ooperabel) eller Steg IV MelanomKanada
-
Parker Institute for Cancer ImmunotherapyBristol-Myers Squibb; Cancer Research Institute, New York CityAvslutadAvancerad metastaserande cancer | Avancerad prostatacancerFörenta staterna
-
Sidney Kimmel Comprehensive Cancer Center at Johns...RekryteringIcke-småcellig lungcancerFörenta staterna
-
Dana-Farber Cancer InstituteBristol-Myers SquibbRekryteringMeningiomFörenta staterna
-
Novo Nordisk A/SAvslutadDiabetes mellitus, typ 2Tyskland
-
Reata, a wholly owned subsidiary of BiogenAvslutadMelanom | Ooperabelt (stadium III) melanom | Metastaserande (stadium IV) melanomFörenta staterna
-
Autoimmune Technologies, LLCAvslutad
-
Universitair Ziekenhuis BrusselRekryteringFast tumör | Icke småcellig lungcancerBelgien